company background image
HXL

Hexima ASX:HXL Stock Report

Last Price

AU$0.018

Market Cap

AU$3.0m

7D

-5.3%

1Y

-95.5%

Updated

01 Dec, 2022

Data

Company Financials
HXL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

HXL Stock Overview

Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics.

Hexima Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hexima
Historical stock prices
Current Share PriceAU$0.018
52 Week HighAU$0.45
52 Week LowAU$0.01
Beta0
1 Month Change-10.00%
3 Month Change28.57%
1 Year Change-95.50%
3 Year Changen/a
5 Year Changen/a
Change since IPO-90.77%

Recent News & Updates

Recent updates

Is Hexima (ASX:HXL) In A Good Position To Invest In Growth?

Mar 21
Is Hexima (ASX:HXL) In A Good Position To Invest In Growth?

Here's Why We're A Bit Worried About Hexima's (ASX:HXL) Cash Burn Situation

Sep 06
Here's Why We're A Bit Worried About Hexima's (ASX:HXL) Cash Burn Situation

Read This Before Selling Hexima Limited (ASX:HXL) Shares

Mar 02
Read This Before Selling Hexima Limited (ASX:HXL) Shares

Shareholder Returns

HXLAU BiotechsAU Market
7D-5.3%0.4%0.5%
1Y-95.5%-4.4%-2.0%

Return vs Industry: HXL underperformed the Australian Biotechs industry which returned -4.4% over the past year.

Return vs Market: HXL underperformed the Australian Market which returned -2% over the past year.

Price Volatility

Is HXL's price volatile compared to industry and market?
HXL volatility
HXL Average Weekly Movement20.0%
Biotechs Industry Average Movement8.9%
Market Average Movement9.0%
10% most volatile stocks in AU Market16.0%
10% least volatile stocks in AU Market4.1%

Stable Share Price: HXL is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 20% a week.

Volatility Over Time: HXL's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1997n/aNicole van der Weerdenhttps://www.hexima.com.au

Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company’s lead drug candidate is the plant defensin, pezadeftide, which is in phase IIb clinical trials for the treatment of fungal toenail infections in Australia and New Zealand. Hexima Limited was incorporated in 1997 and is based in Preston, Australia.

Hexima Limited Fundamentals Summary

How do Hexima's earnings and revenue compare to its market cap?
HXL fundamental statistics
Market CapAU$3.01m
Earnings (TTM)-AU$10.02m
Revenue (TTM)AU$5.81m

0.5x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HXL income statement (TTM)
RevenueAU$5.81m
Cost of RevenueAU$361.87k
Gross ProfitAU$5.45m
Other ExpensesAU$15.47m
Earnings-AU$10.02m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.06
Gross Margin93.77%
Net Profit Margin-172.45%
Debt/Equity Ratio0.0%

How did HXL perform over the long term?

See historical performance and comparison